FENNEC PHARMACEUTICALS INC. (FENC) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 44 days, typically, give or take 21 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q4 FY2025Tue, Mar 24, 2026after close 83 8-K
Q4 FY2024Mon, Mar 10, 2025after close 69 8-K
Q4 FY2023Mon, Mar 25, 2024after close 85 8-K
Q3 FY2023Mon, Nov 6, 2023after close 37 8-K
Q2 FY2023Fri, Aug 4, 2023during market hours 35 8-K
Q4 FY2019Fri, Feb 14, 2020during market hours 45 8-K
Q3 FY2019Tue, Nov 12, 2019during market hours 43 8-K
Q2 FY2019Fri, Aug 9, 2019during market hours 40 8-K

What they guided beta

Q4 FY2025 "The complete unaudited condensed consolidated financial statements for the period ended December 31, 2025, and management's discussion and analysis of financial condition and results of operations will be available via www.sec.gov and www.sedar.com ." exhibit
Q4 FY2024 "EX-99.1 2 fencf-20250310xex99d1.htm EX-99.1 Exhibit 99.1 FENNEC PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ​ ~ Achieved Full-Year PEDMARK ® Net Product Sales of $29.6 Million, Up 40% Year-Over-Year, and Generated PEDMARK ® Q4 2024 Net Product Sales of $7.9 Million ~ ​ ~ Delivered Q4 2024 EBITDA Loss of $0.6 Million and Company Has $26.6 Million in Cash, Cash Equivalents and Short-Term Investments ~ ​ ~ Completed Early Repayment of $13 Million of the Company’s Convertible Debt Facility ~ ​ ~ Continued Momentum in the Adolescent and " exhibit
Q4 FY2024 "PEDMARQSI Ò Commercial Launch in Europe : In December 2024, Norgine received positive guidance from National Institute for Health and Care Excellence (NICE) recommending PEDMARQSI ® for the prevention of cisplatin-induced hearing loss in patients (aged 1 month to 17 years) with localized, non-metastatic, solid tumors and PEDMARQSI ® is currently available in the U.K." exhibit
Q4 FY2024 "Ex-U.S. Opportunities for PEDMARK Ò : In Japan, the investigator-initiated clinical trial (STS-J01) in Japan evaluating PEDMARK Ò fully enrolled in Q4 2024 and the results of the trial are expected in the second half of 2025 with the potential evaluation for registration of PEDMARK ® in Japan thereafter." exhibit
Q4 FY2024 "For the fourth quarter of 2024, G&A expenses decreased due largely to lower cash based stock compensation and a one-time severance payment related to the previous CEO in the third quarter." exhibit
Q4 FY2024 "The complete audited condensed consolidated financial statements for the period ended December 31, 2024 and management's discussion and analysis of financial condition and results of operations will be available via www.sec.gov and www.sedar.com ." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/FENC
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/FENC

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

FENC earnings date badge

HTML

<a href="https://veritasdata.dev/company/FENC/"><img src="https://veritasdata.dev/embed/FENC.svg" alt="FENC earnings date" width="240" height="56"></a>

Markdown

[![FENC earnings date](https://veritasdata.dev/embed/FENC.svg)](https://veritasdata.dev/company/FENC/)

Script

<script async src="https://veritasdata.dev/embed/FENC.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/FENC"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.